Epigenetic regulation of HGK/MAP4K4 in T cells of type 2 diabetes patients

Huai-Chia Chuang; Jun-Sing Wang; I-Te Lee; Wayne H-H. Sheu; Tse-Hua Tan

doi:10.18632/oncotarget.7686

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers: Immunology:

Epigenetic regulation of HGK/MAP4K4 in T cells of type 2 diabetes patients

Huai-Chia Chuang _, Jun-Sing Wang, I-Te Lee, Wayne H-H. Sheu and Tse-Hua Tan

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:10976-10989. https://doi.org/10.18632/oncotarget.7686

Metrics: PDF 2003 views | HTML 3201 views | ?

Abstract

Huai-Chia Chuang1, Jun-Sing Wang2, I-Te Lee2, Wayne H-H. Sheu2,3,* and Tse-Hua Tan1,4,*

1 Immunology Research Center, National Health Research Institutes, Zhunan, Taiwan

2 Division of Endocrinology and Metabolism, Taichung Veterans General Hospital, Taichung, Taiwan

3 Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan

4 Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA

* These authors have contributed equally to this work

Correspondence to:

Tse-Hua Tan, email:

Wayne H-H. Sheu, email:

Keywords: type 2 diabetes, HGK methylation, HGK downregulation, IL-6-producing T cells, Immunology and Microbiology Section, Immune response, Immunity

Received: October 15, 2015 Accepted: February 05, 2016 Published: February 24, 2016

Abstract

Type 2 diabetes (T2D) is a complex and heterogeneous disease. Obesity increases the risk of obese T2D; but in Asia non-obese T2D is prevalent. The cause of non-obese T2D has remained elusive. We studied the potential involvement of HGK/MAP4K4 in T2D using clinical samples from newly diagnosed, drug-naïve patients and healthy controls. HGK levels fell and IL-6 levels increased in T cells from T2D patients. Frequencies of IL-6-producing T cells were correlated with glucose levels after glucose-tolerance tests (but not body mass index and waist circumference) and inversely correlated with HGK expression levels. Moreover, methylation frequencies of the HGK promoter were increased in T2D patients and correlated with glucose levels after glucose-tolerance tests. The correlation was independent of body mass index. Demethylation treatment increased HGK expression levels and reduced IL-6 production in T2D T cells. This report identifies HGK methylation/downregulation in T cells as a potential biomarker for non-obese T2D.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7686

Publication Alerts

Research Papers: Immunology:

Epigenetic regulation of HGK/MAP4K4 in T cells of type 2 diabetes patients

Abstract